latest update:
[TrialBase DB]

trial summary · NCT07668817

Tract Closure in PCNL

Defining the Role of Hemostatic Agents in Percutaneous Nephrolithotomy: A Randomized Controlled Trial of Tract Closure Techniques

Trial record from the TrialBase DB dataset, status RECRUITING, condition Nephrolithiasis, sponsored by Icahn School of Medicine at Mount Sinai. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07668817phase —enrollment 92start 2026-10-26

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This is a prospective, randomized controlled trial evaluating the effect of a hemostatic agent on tract-related bleeding during percutaneous nephrolithotomy (PCNL). Patients undergoing standardized PCNL will be randomized to receive either application of a hemostatic agent or no agent during tract closure, following uniform balloon occlusion, complete aspiration, and irrigation-free endoscopic assessment. The researchers hypothesize that adjunctive hemostatic agent use reduces perioperative hemoglobin decline compared with balloon tamponade alone and improves tract-related hemostasis outcomes.

Source record: https://clinicaltrials.gov/study/NCT07668817

Facts

registry idNCT07668817
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasenot reported
study typeINTERVENTIONAL
lead conditionNephrolithiasis
sponsorIcahn School of Medicine at Mount Sinai
sponsor classOTHER
enrollment92
start date2026-10-26
primary completion2028-05
completion2028-06
results postednot reported

Conditions

  • Nephrolithiasis

Interventions

  • Floseal
  • Surgicel
  • Surgiflo
  • Balloon Tamponade

Countries

  • United States

Intervention types: DEVICE, PROCEDURE

Work with this record